P roliferative vitreoretinopathy (PVR) is a major cause of persistent reduction in visual acuity after retinal detachment or severe ocular trauma. [1] [2] [3] Clinically, PVR is characterized by the dispersion and proliferation of retinal pigment epithelial cells in the vitreous and the subsequent formation of membranes on both retinal surfaces. 4, 5 The contraction of these epiretinal and subretinal membranes results in tractional retinal detachment or redetachment.
Retinal pigment epithelial (RPE) cells seem to play a major role in PVR development (e.g., in retinal membrane formation and as a contractile force resulting in complex retinal redetachment). 6, 7 The cascade of cellular events leading to PVR is cell mediated and stimulated by serum and/or a variety of growth factors. 8, 9 Initial events in this cellular cascade are attachment to the retinal surface, spreading along the surface, and migration with subsequent formation of cellular membranes. 10 Later cellular events present as proliferation and cell-mediated contraction of retinal membranes resulting in redetachment of the retina.
Pharmacologic prevention of PVR membrane formation has been based chiefly on antiproliferative and anti-inflammatory agents. [11] [12] [13] [14] Although many of these substances lack efficacy and may even have toxic side effects, some of them seem to reduce PVR recurrence. 11 However, no pharmacological adjuvant has been established as part of a routine treatment for PVR, as recent reviews of the current literature show. 15, 16 In previous in vitro studies, we have shown that alkylphosphocholines (APCs) are effective inhibitors of human RPE cell proliferation and RPE-mediated collagen contraction at nontoxic concentrations. 17 APCs are a new class of pharmacological agents in routine clinical use with known antitumoral (Miltex; Zentaris GmbH, Frankfurt, Germany) and antiparasitic (Impavido; Zentaris GmbH) properties. 18, 19 The mode of action of APCs is mediated by the cell membrane and involves the inhibition of protein kinase C in human RPE cells 17 as well as in other cellular systems in vitro. 20, 21 The activation of PKC seems to be an important feature, not only in the late phase of PVR, as in RPE-mediated membrane contraction, 22 but also during the early cellular events of PVR development, as in cellular migration, 23 adhesion, and spreading. 24 In addition, PKC inhibitors have been implicated in the regulation of microfilament network organization. 25 Thus, a selective inhibition of this pathway by APCs could offer a new perspective on prevention of PVR.
The purpose of this study was to test whether APCs inhibit early cellular events in PVR pathogenesis, such as attachment, spreading and migration of human RPE cells in vitro and to assess microfilament assembly in the presence of serum.
MATERIALS AND METHODS

Alkylphosphocholines
The APCs oleyl-phosphocholine (C18:1-PC), (Z)-10-eicosenyl-phosphocholine (C20:1-PC), (Z)-12-heneicosenyl-phosphocholine (C21:1-PC), and erucyl-phosphocholine (C22:1-PC) were synthesized and kindly provided by Hansjoerg Eibl, PhD, (Göttingen, Germany), as described previously. 17 All substances were dissolved in ethanol and stored at 4°C. Independent dilution series in ethanol were used to obtain final concen-trations of APCs in equal volumes of ethanol. Equal volumes of ethanol without addition of APCs served as the control in all experiments performed.
Human RPE Cell Culture
RPE cells were isolated from five human donors, age 20 to 71 years, within 4 to 14 hours after death as described previously 26 and obtained from the Eye Bank of the Ludwig-Maximilians University Munich. Methods for securing human tissue were humane, included proper consent and approval, complied with the Declaration of Helsinki, and were approved by the local ethics committee.
In brief, whole eyes were rinsed with 0.9% NaCl solution, immersed in 5% polyvinyl pyrrolidone iodine, and rinsed again with the sodium-chloride solution. After removal of the anterior segment, the posterior pole of each donor eye was examined with a binocular stereomicroscope to exclude any gross retinal disease. The neuroretina was then carefully peeled away from the RPE layer with a fine forceps. The eye cup was rinsed with Ca 2ϩ -and Mg 2ϩ -free Hank's balanced salt solution and treated with 0.25% trypsin (Invitrogen-Gibco, Karlsruhe, Germany) for 1 hour at 37°C. After aspiration of trypsin, the eye cup was filled with Dulbecco's modified Eagle's medium (DMEM; Biochrom, Berlin, Germany) supplemented with 20% fetal calf serum (FCS; Biochrom). The medium was then gently aspirated with a pipette, to detach RPE into the medium without damaging Bruch's membrane.
The cell suspension was transferred to a 50-mL flask (Falcon; Corning-Costar, Wiesbaden, Germany) containing 20 mL of DMEM supplemented with 20% FCS and maintained at 37°C and 5% carbon dioxide. All cell culture dishes used were uncoated. Epithelial origin was confirmed by immunohistochemical staining for cytokeratin using a pancytokeratin antibody (Sigma-Aldrich, Deisenhofen, Germany) as described previously (data not shown). 27 The cells were tested and found free of contaminating macrophages (anti-CD11, Sigma-Aldrich) and endothelial cells (anti-von Willebrand factor; Sigma-Aldrich; data not shown).
Several primary cell cultures were grown to confluence. Subcultures between the third and sixth passages (passages 3-6) were maintained with DMEM containing 10% FCS at 37°C and 5% carbon dioxide. In the present study, RPE cells of five human donors were used when cells were actively proliferating.
Cell Attachment Assay
Ninety-six well plates (Nunc, Wiesbaden, Germany) were coated with 70 L/well fibronectin (50 g/mL in PBS [pH 7.4]; Sigma-Aldrich) for 16 hours at 4°C. Unspecific binding was blocked by 2 mg/mL ovalbumin (Sigma-Aldrich) in PBS for 1 hour at 37°C as described previously. 28 RPE cells (passages 3-6) were seeded in 96-well plates (Nunc) at a density of 1 ϫ 10 6 cells per well in 1 mL DMEM, 10% FCS. APCs were added in concentrations spanning the 50% inhibitory concentration (IC 50 ) interval between 0.01 and 50 M, as determined in preliminary assays. 17 The IC 50 is defined as the concentration of a drug that produces a 50% reduction in cell number at nontoxic concentrations. After 2 hours, RPE cells were then carefully washed three times with PBS using an automated plate washer (Molecular Devices, Garching, Germany).
After the washing step, the number of attached RPE cells was determined by the tetrazolium dye-reduction assay [MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide]; Sigma-Aldrich). The MTT test was performed as described by Mosmann, 29 with some modifications. In brief, 200 L/well MTT solution (1.5 mL MTT stock [2 mg/mL in PBS] plus 28.5 mL DMEM) was added. RPE cells were incubated at 37°C for 1 hour and carefully observed to exclude crystal formation outside of cells. Formazan crystals formed were then dissolved by the addition of dimethyl sulfoxide (DMSO; 200 L/well). The final concentration of DMSO in the cell culture medium was found to have no antiproliferative effect on RPE cells. Absorption was measured by a scanning multiwell spectrophotometer at 550 nm (Molecular Probes, Göttingen, Germany). The number of attached living cells correlated with the absorbance (optical density, OD) measured by the MTT at 550 nm. Results from the wells were expressed as the mean percentage of the control (control OD 0.6 at 550 nm assigned as 100%). Experiments were performed in triplicate and repeated four times. RPE cells of the same passage number incubated with equal volumes of ethanol without addition of APCs served as the control.
Cell Spreading Assay
For analysis of cell spreading, 24-well plates (Nunc) were coated with 70 L/well fibronectin (50 g/mL in PBS, pH 7,4; Sigma-Aldrich) for 16 hours at 4°C. Unspecific binding was blocked by 2 mg/mL ovalbumin (Sigma-Aldrich) in PBS for 1 hour at 37°C, as described previously. 10 Human RPE cells (passages 3-6) were seeded at a density of 5 ϫ 10 4 cells per well on the fibronectin-coated wells in 1 mL DMEM and 10% FCS. APCs were added in concentrations spanning the 50% inhibitory RPE cells, as determined previously. 17 RPE cells were allowed to spread for 4 hours at 37°C and 5% CO 2 . After they were washed with PBS three times, cells were fixed with 4% paraformaldehyde in PBS, and then stained with Coomassie brilliant blue for 3 to 4 minutes and rinsed again with PBS. For quantification of cell spreading, four separate fields were photo-documented with a phase contrast microscope (Leica, Heidelberg, Germany). Cell spreading was characterized by the formation of a clearly defined cytoplasmic halo around the cell nucleus. RPE cells demonstrating this phenomenon were counted and the percentage of the total number of RPE cells per field was calculated.
Results from the wells were expressed as the mean percentage of the control. Experiments were performed in triplicate and repeated four times. RPE cells of the same passage number incubated with equal volumes of ethanol without addition of APCs served as the control.
Cell Migration Assay
Migration was determined by a modification of the Boyden's chamber method using microchemotaxis chambers (NeuroProbe, Gaithersburg, MD) and polycarbonate filters (Nucleopore, Karlsruhe, Germany) with a pore size of 8.0 m. 30 The filters were coated with fibronectin and placed between the chambers. The lower half of the Boyden chamber was filled with 125 L DMEM containing 20 ng/mL human recombinant platelet-derived growth factor (PDGF-BB; PeproTech, London, UK). Human RPE cells (passages [3] [4] [5] [6] were then suspended at a density of 5 ϫ 10 5 cells/mL in DMEM and 0.5% FCS and placed in the upper half of the Boyden chamber (500 L). APCs were added in concentrations spanning the 50% inhibitory RPE cells, as determined previously. 17 The cells were incubated 6 hours at 37°C in 5% CO 2 . After the upper side of the filter was scraped with a cotton tip to eliminate RPE cells that had not migrated through it, the filter was removed and fixed in methanol before staining with hematoxylin. Cell number in five fields chosen randomly was determined at a magnification of ϫ200 using a phase contrast microscope (Leica). Experiments were performed in triplicate and repeated four times. RPE cells of the same passage number incubated with equal volumes of ethanol without addition of APCs served as the control.
Immunofluorescence Analysis of Microfilaments
Microfilament organization of human RPE cells (passages 3-6) was assessed by a modification of the immunofluorescence analysis protocol with rhodamine-phalloidin (AlexaFluor 488 phalloidin A 12379; Molecular Probes, Inc.), as described elsewhere. 25 Cells were seeded in chamber slides (2 ϫ 10 4 cells/well in DMEM and 10% FCS). After incubation for 4 hours at 37°C in 5% CO 2 , the medium was aspirated and adherent cells were fixed with 3.7% paraformaldehyde in PBS for 10 minutes at 20°C. After they were washed with PBS (pH 7.4), the cells were permeabilized with 0.1% Triton X-100 for 3 minutes and blocked with 1% BSA (bovine serum albumin) in PBS. Cells were then incubated with rhodamine-phalloidin (200 U/mL) and Hoechst stain (1 g/mL) for 20 minutes in the dark. PBS was used as the base of all solutions and intervening rinses, and incubations were performed at room temperature. After mounting (Kaiser's Glyceringelatine; Merck, 
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Statistical Evaluation
Statistical analysis was performed (SPSS V 11.0; SPSS Inc., Chicago, IL). All results are expressed as the mean Ϯ SEM as indicated. For determination of the significance of differences an ANOVA was performed. Differences with P Ͻ 0.01 were considered statistically significant.
RESULTS
Inhibition of RPE Cell Attachment by APCs
All APCs investigated inhibited attachment of human retinal pigment epithelium cells on fibronectin-coated cell culture dishes in a dose-dependent manner in vitro ( Fig. 1) . At the same concentration, however, APCs with a longer carbon chain of more than C20 were more effective than C18:1-PC. This finding correlates well with the difference in the IC 50 concentration determined previously 17 (Table 1) . Consequently, the APC with the highest IC 50 of approximately 30 M, C18:1-PC, has the lowest efficacy in the inhibition of RPE cell attachment compared with those of C20:1-PC, C21:1-PC, and C22:1-PC with an IC 50 of only approximately 10 M.
Oleyl-phosphocholine (C18:1-PC) displayed an inhibition of RPE cell attachment at concentrations between 0.1 and 50 M (Fig. 1) . Cells exposed to C18:1-PC at concentrations below 0.1 M were not significantly compromised in their ability to attach compared with the control. Close to its IC 50 of 26.5 M Ϯ 1.3 (Table 1) , C18:1-PC inhibited attachment of more than 70% of treated RPE cells. At 10 M, 50% of RPE cells did not attach.
All APCs with a carbon chain length of more than C20, eicosenyl-phosphocholine (C20:1-PC) heneicosenyl-phosphocholine (C21:1-PC) and erucyl-phosphocholine (C22:1-PC), inhibited RPE cell attachment at concentrations between 0.01 and 30 M (Fig. 1) . Close to their IC 50 of approximately 10 M, respectively, more than 70% of RPE cells were unable to attach was was shown for C18:1-PC at its IC 50 . However, a 50% inhibition of cell attachment was achieved for all APCs with a carbon chain length of more than 20 at a concentration of only 1 M.
Inhibition by APCs of RPE Cell Spreading
All four APCs applied caused a significant concentration-dependent inhibition of RPE cell spreading on fibronectin-coated cell culture dishes (Fig. 2) . The data suggest a difference in efficacy of the APCs in parallel to that demonstrated for RPE cell attachment. Again, close to their IC 50 , all four APCs were equally effective, achieving an inhibition of RPE spreading in more than 80% of cells. The concentration necessary to induce a spreading inhibition in 50% of cells was even more than 10 times higher for C18:1-PC (10 M) than for all other APCs applied (0.1-1 M). This corresponds well with the findings for RPE cell attachment ( Table 1) .
Inhibition of RPE Cell Migration by APCs
RPE cell migration was inhibited by all four APCs applied in a dose-dependent manner (Fig. 3) . Close to their IC 50 , respectively, each APC inhibited migration in more than 90% of RPE cells (Table 1) . APCs with a longer carbon chain of more than C20 were again far more effective at equal concentrations than was C18:1-PC. The concentration achieving a 50% inhibition of RPE cell migration was 0.1 to 1 M for C20:1-PC, C21:1-PC, and C22:1-PC compared with 10 M for C18:1-PC.
Disturbance of Microfilament Dynamics by APCs
F-actin assembly in human RPE cells was significantly disturbed after incubation with each one of the four APCs applied close to its IC 50 ( Fig. 4c-j Figs. 4i, 4j) . Control cells displayed a well organized actin skeleton with fibers extending throughout the cytoplasm into the cell membrane (Figs. 4a, 4b ).
DISCUSSION
On the cellular level, the development of PVR can be described as a cascade of specific cellular events within the retina and on Effect of the 50% inhibitory concentration (IC 50 ) 17 (in M Ϯ 95% CI) on RPE cell attachment, spreading, and migration for each APC, respectively (% control Ϯ SEM).
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IOVS, January 2006, Vol. 47, No. 1 both retinal surfaces involving the vitreous. Initial cellular events in early PVR can be defined as attachment of RPE cells on the retinal surfaces followed by cytoplasmic spreading and cellular migration along these surfaces. Later stages in PVR pathogenesis are characterized by cellular proliferation and membrane formation with subsequent cell-mediated membrane contraction and tractional redetachment of the retina. In a previous in vitro study, we could demonstrate that APCs are able to inhibit the late stages in PVR development associated with RPE proliferation and cell-mediated membrane contraction. 17 In this study, APCs were found to be effective inhibitors of early cellular events in PVR pathogenesis like RPE cell attachment, spreading, and migration at nontoxic concentrations.
We are aware of the limitations of our results by using fibronectin alone as a substrate for the investigation of key cellular events in early PVR. Alternatively, we and others 31, 32 demonstrated that RPE cells show a clear preference for fibronectin over other provisional extracellular matrix (ECM) components such as collagen type I and laminin in early PVR. 33 Therefore, we believe that the inhibition of RPE cell attachment by APCs on fibronectin is a good example for the potential of these substances. Even if APCs were insufficient in their inhibition of these key cellular events on other provisional ECM substrates, their effect on fibronectin would interfere with early PVR development significantly.
Our data suggest that the effect of APCs on the key cellular events in early PVR is due to an interference of these substances with the microfilament assembly in human RPE cells. The inhibition of PKC activity by APCs 17 seems to be linked with the microfilament assembly in these cells resulting in a decreased ability of the RPE to attach, spread and migrate. 23, 25 Thus, the inhibition of the initial stages in PVR development could prevent a disease progression to the more advanced stages commonly associated with a severe reduction in visual acuity.
In the present in vitro study, we have shown that APCs can inhibit even early cellular events in PVR development at concentrations below the IC 50 17 in a dose-dependent manner in the presence of serum. The dispersion and accumulation of serum components in the vitreous cavity is known to be a crucial event for in vivo PVR development due to a breakdown of the blood-retinal barrier. 34, 35 Serum has been identified as a strong stimulator of RPE proliferation 36 and contains fibrogenic (basic fibroblast growth factor; bFGF) and inflammatory (inter- 37 A new therapeutic approach for the treatment of PVR should therefore be able to act in the presence of these growth factors.
Other pharmacologic agents currently in discussion for PVR treatment have not been effective in the presence of serum and, moreover, are not able to influence all the cellular events mentioned. For example, the most promising combination of 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) has been shown to inhibit RPE proliferation only. 38 Clinically, there was no statistically significant difference in visual outcome of treated versus untreated patients. 34 Daunomycin, another candidate for PVR treatment, inhibits cellular proliferation and migration, but the effective dose seems to be close to the toxic one which has prevented a routine clinical application so far. 39, 40 Also, a combination therapy of dexamethasone and heparin has not shown statistically significant results regarding PVR recurrence with at the same time an increased incidence of postoperative vitreous hemorrhage in the treated group. 41 Because of a lack of efficacy and side effects of these substances, none of them is currently in routine clinical use for the prevention and/or treatment of PVR.
In summary, our results indicate that APCs are able to inhibit not only the late stages of PVR development like RPE cell proliferation and cell-mediated membrane-contraction but also the early cellular events like RPE cell attachment, spreading and migration in a dose-dependent manner at nontoxic concentrations. As a mechanism of action, APCs seem to interfere with microfilament assembly in human RPE cells by inhibition of PKC. The first intraocular in vivo toxicity study of erucylphosphocholine in a rat model displayed no retinal toxicity even at the 10-fold IC 50 when administered intravitreally. 42 Therefore, APCs may become a new treatment option for prevention of PVR.
